WEBVTT
Kind: captions
Language: en

00:00:11.629 --> 00:00:13.970 

the<00:00:12.629> pharmaceutical<00:00:13.169> and<00:00:13.620> molecular

00:00:13.970 --> 00:00:13.980 
the pharmaceutical and molecular

00:00:13.980 --> 00:00:15.890 
the pharmaceutical and molecular
biotechnology<00:00:14.610> research<00:00:15.030> centre<00:00:15.599> was

00:00:15.890 --> 00:00:15.900 
biotechnology research centre was

00:00:15.900 --> 00:00:20.870 
biotechnology research centre was
established<00:00:15.929> in<00:00:16.790> 2008<00:00:18.140> here<00:00:19.140> in<00:00:19.230> Wi<00:00:19.590> T<00:00:19.880> it

00:00:20.870 --> 00:00:20.880 
established in 2008 here in Wi T it

00:00:20.880 --> 00:00:23.240 
established in 2008 here in Wi T it
occupies<00:00:21.330> approximately<00:00:21.650> 700<00:00:22.650> square<00:00:22.800> meters

00:00:23.240 --> 00:00:23.250 
occupies approximately 700 square meters

00:00:23.250 --> 00:00:26.480 
occupies approximately 700 square meters
of<00:00:23.370> research<00:00:24.030> space<00:00:24.330> and<00:00:25.010> today<00:00:26.010> aged<00:00:26.190> as

00:00:26.480 --> 00:00:26.490 
of research space and today aged as

00:00:26.490 --> 00:00:29.090 
of research space and today aged as
approximately<00:00:27.210> 25<00:00:27.840> staff<00:00:28.200> involved<00:00:28.680> in<00:00:29.010> the

00:00:29.090 --> 00:00:29.100 
approximately 25 staff involved in the

00:00:29.100 --> 00:00:31.910 
approximately 25 staff involved in the
center<00:00:29.570> the<00:00:30.570> purpose<00:00:30.990> of<00:00:31.230> the<00:00:31.620> pharmaceutical

00:00:31.910 --> 00:00:31.920 
center the purpose of the pharmaceutical

00:00:31.920 --> 00:00:33.680 
center the purpose of the pharmaceutical
Malaysia<00:00:32.279> biotechnology<00:00:33.000> research<00:00:33.120> center

00:00:33.680 --> 00:00:33.690 
Malaysia biotechnology research center

00:00:33.690 --> 00:00:36.380 
Malaysia biotechnology research center
was<00:00:34.080> a<00:00:34.410> factory<00:00:35.100> there<00:00:35.430> was<00:00:35.490> three<00:00:36.180> key

00:00:36.380 --> 00:00:36.390 
was a factory there was three key

00:00:36.390 --> 00:00:37.610 
was a factory there was three key
strands<00:00:36.750> that<00:00:36.960> we<00:00:37.080> were<00:00:37.140> trying<00:00:37.320> to<00:00:37.440> support

00:00:37.610 --> 00:00:37.620 
strands that we were trying to support

00:00:37.620 --> 00:00:40.970 
strands that we were trying to support
in<00:00:38.040> the<00:00:38.130> center<00:00:38.370> one<00:00:39.180> was<00:00:39.960> to<00:00:40.770> support

00:00:40.970 --> 00:00:40.980 
in the center one was to support

00:00:40.980 --> 00:00:43.970 
in the center one was to support
innovation<00:00:41.400> in<00:00:42.120> the<00:00:42.210> southeast<00:00:42.600> in<00:00:43.500> terms<00:00:43.829> of

00:00:43.970 --> 00:00:43.980 
innovation in the southeast in terms of

00:00:43.980 --> 00:00:45.530 
innovation in the southeast in terms of
multinational<00:00:44.550> companies<00:00:44.670> say<00:00:45.000> for<00:00:45.150> example

00:00:45.530 --> 00:00:45.540 
multinational companies say for example

00:00:45.540 --> 00:00:49.069 
multinational companies say for example
and<00:00:45.660> SMEs<00:00:46.700> secondly<00:00:47.700> was<00:00:48.090> to<00:00:48.780> support

00:00:49.069 --> 00:00:49.079 
and SMEs secondly was to support

00:00:49.079 --> 00:00:50.870 
and SMEs secondly was to support
postgraduate<00:00:49.829> training<00:00:49.950> at<00:00:50.280> master's<00:00:50.730> and

00:00:50.870 --> 00:00:50.880 
postgraduate training at master's and

00:00:50.880 --> 00:00:55.340 
postgraduate training at master's and
PhD<00:00:51.329> level<00:00:52.020> and<00:00:52.550> thirdly<00:00:53.550> was<00:00:54.060> to<00:00:54.420> develop<00:00:55.110> and

00:00:55.340 --> 00:00:55.350 
PhD level and thirdly was to develop and

00:00:55.350 --> 00:00:58.790 
PhD level and thirdly was to develop and
support<00:00:55.760> training<00:00:56.760> and<00:00:57.440> partnerships<00:00:58.440> with

00:00:58.790 --> 00:00:58.800 
support training and partnerships with

00:00:58.800 --> 00:01:01.660 
support training and partnerships with
EU<00:00:59.550> organisations<00:01:00.390> both<00:01:00.660> companies<00:01:01.140> and

00:01:01.660 --> 00:01:01.670 
EU organisations both companies and

00:01:01.670 --> 00:01:06.190 
EU organisations both companies and
third<00:01:02.670> level<00:01:03.000> organisations<00:01:03.690> as<00:01:03.870> well

00:01:06.190 --> 00:01:06.200 

00:01:06.200 --> 00:01:07.999 

collaboration<00:01:07.200> with<00:01:07.229> industry<00:01:07.439> is<00:01:07.979> a

00:01:07.999 --> 00:01:08.009 
collaboration with industry is a

00:01:08.009 --> 00:01:09.830 
collaboration with industry is a
significant<00:01:08.670> proportion<00:01:08.969> of<00:01:09.359> the<00:01:09.509> work<00:01:09.659> that

00:01:09.830 --> 00:01:09.840 
significant proportion of the work that

00:01:09.840 --> 00:01:12.830 
significant proportion of the work that
we<00:01:09.929> do<00:01:10.049> here<00:01:10.259> in<00:01:10.530> the<00:01:10.770> PM<00:01:11.009> BRC<00:01:11.460> at<00:01:12.299> the<00:01:12.509> projects

00:01:12.830 --> 00:01:12.840 
we do here in the PM BRC at the projects

00:01:12.840 --> 00:01:14.510 
we do here in the PM BRC at the projects
that<00:01:12.929> we<00:01:13.079> do<00:01:13.229> range<00:01:13.560> from<00:01:13.770> small<00:01:13.950> one<00:01:14.369> of

00:01:14.510 --> 00:01:14.520 
that we do range from small one of

00:01:14.520 --> 00:01:17.449 
that we do range from small one of
contract<00:01:15.179> analysis<00:01:15.659> and<00:01:16.459> quantity

00:01:17.449 --> 00:01:17.459 
contract analysis and quantity

00:01:17.459 --> 00:01:19.669 
contract analysis and quantity
investigations<00:01:18.119> right<00:01:18.689> up<00:01:18.899> to<00:01:19.109> development

00:01:19.669 --> 00:01:19.679 
investigations right up to development

00:01:19.679 --> 00:01:21.169 
investigations right up to development
of<00:01:19.740> new<00:01:19.799> products<00:01:20.340> and<00:01:20.490> new<00:01:20.549> technologies

00:01:21.169 --> 00:01:21.179 
of new products and new technologies

00:01:21.179 --> 00:01:22.489 
of new products and new technologies
which<00:01:21.389> are<00:01:21.539> obviously<00:01:21.869> more<00:01:22.020> extensive

00:01:22.489 --> 00:01:22.499 
which are obviously more extensive

00:01:22.499 --> 00:01:24.559 
which are obviously more extensive
collaborations<00:01:23.100> the<00:01:23.819> companies<00:01:24.209> we<00:01:24.299> work

00:01:24.559 --> 00:01:24.569 
collaborations the companies we work

00:01:24.569 --> 00:01:26.870 
collaborations the companies we work
with<00:01:24.780> tend<00:01:25.350> to<00:01:25.530> be<00:01:25.679> in<00:01:25.950> the<00:01:26.459> pharmaceutical

00:01:26.870 --> 00:01:26.880 
with tend to be in the pharmaceutical

00:01:26.880 --> 00:01:28.309 
with tend to be in the pharmaceutical
and<00:01:27.240> healthcare<00:01:27.270> and<00:01:27.810> medical<00:01:28.020> device

00:01:28.309 --> 00:01:28.319 
and healthcare and medical device

00:01:28.319 --> 00:01:31.639 
and healthcare and medical device
industries<00:01:29.659> searching<00:01:30.659> the<00:01:30.719> PMB<00:01:31.139> our<00:01:31.259> C<00:01:31.439> can

00:01:31.639 --> 00:01:31.649 
industries searching the PMB our C can

00:01:31.649 --> 00:01:33.949 
industries searching the PMB our C can
be<00:01:31.679> broken<00:01:31.920> down<00:01:32.189> into<00:01:32.399> four<00:01:32.490> areas<00:01:33.060> our<00:01:33.359> drug

00:01:33.949 --> 00:01:33.959 
be broken down into four areas our drug

00:01:33.959 --> 00:01:36.050 
be broken down into four areas our drug
delivery<00:01:34.289> research<00:01:34.619> is<00:01:34.920> aimed<00:01:35.490> at<00:01:35.789> delivering

00:01:36.050 --> 00:01:36.060 
delivery research is aimed at delivering

00:01:36.060 --> 00:01:38.569 
delivery research is aimed at delivering
drugs<00:01:36.569> more<00:01:36.810> effectively<00:01:37.350> to<00:01:37.889> target<00:01:38.369> sites

00:01:38.569 --> 00:01:38.579 
drugs more effectively to target sites

00:01:38.579 --> 00:01:40.340 
drugs more effectively to target sites
within<00:01:38.850> the<00:01:38.969> body<00:01:39.149> with<00:01:39.810> the<00:01:39.929> aim<00:01:40.109> of

00:01:40.340 --> 00:01:40.350 
within the body with the aim of

00:01:40.350 --> 00:01:42.590 
within the body with the aim of
improving<00:01:41.009> the<00:01:41.549> therapeutic<00:01:42.060> benefit<00:01:42.420> to<00:01:42.509> the

00:01:42.590 --> 00:01:42.600 
improving the therapeutic benefit to the

00:01:42.600 --> 00:01:45.289 
improving the therapeutic benefit to the
patient<00:01:42.779> and<00:01:43.340> minimizing<00:01:44.340> the<00:01:44.369> peasant

00:01:45.289 --> 00:01:45.299 
patient and minimizing the peasant

00:01:45.299 --> 00:01:47.179 
patient and minimizing the peasant
side-effects<00:01:45.749> that<00:01:45.840> some<00:01:46.079> drugs<00:01:46.319> can<00:01:46.619> have<00:01:46.829> on

00:01:47.179 --> 00:01:47.189 
side-effects that some drugs can have on

00:01:47.189 --> 00:01:50.149 
side-effects that some drugs can have on
the<00:01:47.490> patient<00:01:47.880> our<00:01:48.329> biomedical<00:01:49.200> research<00:01:49.709> we

00:01:50.149 --> 00:01:50.159 
the patient our biomedical research we

00:01:50.159 --> 00:01:52.760 
the patient our biomedical research we
are<00:01:50.279> looking<00:01:50.520> at<00:01:50.819> new<00:01:51.349> biomarkers<00:01:52.349> which<00:01:52.590> can

00:01:52.760 --> 00:01:52.770 
are looking at new biomarkers which can

00:01:52.770 --> 00:01:54.739 
are looking at new biomarkers which can
be<00:01:52.889> used<00:01:53.069> the<00:01:53.520> early<00:01:53.789> diagnosis<00:01:54.299> of<00:01:54.479> certain

00:01:54.739 --> 00:01:54.749 
be used the early diagnosis of certain

00:01:54.749 --> 00:01:56.089 
be used the early diagnosis of certain
diseases<00:01:54.869> such<00:01:55.409> as<00:01:55.439> cancers<00:01:55.950> of

00:01:56.089 --> 00:01:56.099 
diseases such as cancers of

00:01:56.099 --> 00:01:58.179 
diseases such as cancers of
cardiovascular<00:01:56.399> disease<00:01:56.999> our

00:01:58.179 --> 00:01:58.189 
cardiovascular disease our

00:01:58.189 --> 00:02:00.589 
cardiovascular disease our
pharmaceutical<00:01:59.189> analysis<00:01:59.909> research<00:02:00.090> into<00:02:00.479> P

00:02:00.589 --> 00:02:00.599 
pharmaceutical analysis research into P

00:02:00.599 --> 00:02:02.749 
pharmaceutical analysis research into P
and<00:02:00.719> B<00:02:00.840> or<00:02:00.959> C<00:02:01.139> we're<00:02:01.679> looking<00:02:01.950> at<00:02:02.189> separation

00:02:02.749 --> 00:02:02.759 
and B or C we're looking at separation

00:02:02.759 --> 00:02:05.149 
and B or C we're looking at separation
science<00:02:03.270> and<00:02:03.450> analytical<00:02:04.229> separations<00:02:04.829> and

00:02:05.149 --> 00:02:05.159 
science and analytical separations and

00:02:05.159 --> 00:02:07.219 
science and analytical separations and
also<00:02:05.700> using<00:02:06.299> our<00:02:06.659> characterization

00:02:07.219 --> 00:02:07.229 
also using our characterization

00:02:07.229 --> 00:02:09.319 
also using our characterization
technologies<00:02:08.099> to<00:02:08.310> characterize<00:02:08.729> drugs<00:02:09.090> and

00:02:09.319 --> 00:02:09.329 
technologies to characterize drugs and

00:02:09.329 --> 00:02:10.050 
technologies to characterize drugs and
except<00:02:09.599> in

00:02:10.050 --> 00:02:10.060 
except in

00:02:10.060 --> 00:02:12.990 
except in
and<00:02:10.149> relation<00:02:11.140> to<00:02:11.170> those<00:02:11.290> properties<00:02:11.560> to<00:02:12.250> the

00:02:12.990 --> 00:02:13.000 
and relation to those properties to the

00:02:13.000 --> 00:02:14.280 
and relation to those properties to the
performance<00:02:13.750> of<00:02:13.810> the<00:02:13.930> drug<00:02:14.110> on<00:02:14.230> a

00:02:14.280 --> 00:02:14.290 
performance of the drug on a

00:02:14.290 --> 00:02:16.470 
performance of the drug on a
manufacturing<00:02:14.860> process<00:02:15.280> or<00:02:15.430> the<00:02:16.030> efficacy<00:02:16.209> of

00:02:16.470 --> 00:02:16.480 
manufacturing process or the efficacy of

00:02:16.480 --> 00:02:19.170 
manufacturing process or the efficacy of
the<00:02:16.690> final<00:02:16.959> product<00:02:17.260> itself<00:02:18.000> finally<00:02:19.000> our

00:02:19.170 --> 00:02:19.180 
the final product itself finally our

00:02:19.180 --> 00:02:21.150 
the final product itself finally our
research<00:02:19.510> in<00:02:19.630> molecular<00:02:19.720> biotechnology<00:02:20.500> and

00:02:21.150 --> 00:02:21.160 
research in molecular biotechnology and

00:02:21.160 --> 00:02:22.800 
research in molecular biotechnology and
we're<00:02:21.580> looking<00:02:21.790> at<00:02:21.880> novel<00:02:22.060> enzymes<00:02:22.540> which<00:02:22.780> can

00:02:22.800 --> 00:02:22.810 
we're looking at novel enzymes which can

00:02:22.810 --> 00:02:24.449 
we're looking at novel enzymes which can
be<00:02:23.080> used<00:02:23.260> in<00:02:23.440> the<00:02:23.560> selected<00:02:23.980> synthesis<00:02:24.430> of

00:02:24.449 --> 00:02:24.459 
be used in the selected synthesis of

00:02:24.459 --> 00:02:26.190 
be used in the selected synthesis of
certain<00:02:24.880> organic<00:02:25.090> molecules<00:02:25.690> which<00:02:26.170> can

00:02:26.190 --> 00:02:26.200 
certain organic molecules which can

00:02:26.200 --> 00:02:28.170 
certain organic molecules which can
ultimately<00:02:26.830> be<00:02:26.950> used<00:02:27.069> in<00:02:27.489> the<00:02:27.580> synthesis<00:02:28.030> of

00:02:28.170 --> 00:02:28.180 
ultimately be used in the synthesis of

00:02:28.180 --> 00:02:32.040 
ultimately be used in the synthesis of
drug<00:02:28.450> molecules<00:02:30.239> the<00:02:31.239> pharmaceutical

00:02:32.040 --> 00:02:32.050 
drug molecules the pharmaceutical

00:02:32.050 --> 00:02:33.870 
drug molecules the pharmaceutical
molecular<00:02:32.410> biotechnology<00:02:33.010> Research<00:02:33.519> Center

00:02:33.870 --> 00:02:33.880 
molecular biotechnology Research Center

00:02:33.880 --> 00:02:35.970 
molecular biotechnology Research Center
one<00:02:34.180> of<00:02:34.209> the<00:02:34.390> reasons<00:02:34.959> for<00:02:35.200> setting<00:02:35.680> it<00:02:35.769> up<00:02:35.830> in

00:02:35.970 --> 00:02:35.980 
one of the reasons for setting it up in

00:02:35.980 --> 00:02:38.910 
one of the reasons for setting it up in
the<00:02:36.040> first<00:02:36.250> place<00:02:36.340> was<00:02:37.209> to<00:02:37.360> support<00:02:37.920> high-end

00:02:38.910 --> 00:02:38.920 
the first place was to support high-end

00:02:38.920 --> 00:02:41.880 
the first place was to support high-end
jobs<00:02:39.370> in<00:02:39.790> the<00:02:39.910> Southeast<00:02:40.330> region<00:02:40.690> and<00:02:40.900> we've

00:02:41.880 --> 00:02:41.890 
jobs in the Southeast region and we've

00:02:41.890 --> 00:02:45.330 
jobs in the Southeast region and we've
achieved<00:02:42.040> that<00:02:42.370> in<00:02:43.330> two<00:02:43.930> ways<00:02:44.110> one<00:02:44.410> is<00:02:44.799> through

00:02:45.330 --> 00:02:45.340 
achieved that in two ways one is through

00:02:45.340 --> 00:02:47.160 
achieved that in two ways one is through
the<00:02:45.610> funding<00:02:45.970> of<00:02:46.060> projects<00:02:46.510> with<00:02:46.690> industry

00:02:47.160 --> 00:02:47.170 
the funding of projects with industry

00:02:47.170 --> 00:02:49.440 
the funding of projects with industry
and<00:02:47.350> the<00:02:48.130> knock-on<00:02:48.430> effects<00:02:48.790> those<00:02:48.970> projects

00:02:49.440 --> 00:02:49.450 
and the knock-on effects those projects

00:02:49.450 --> 00:02:51.479 
and the knock-on effects those projects
have<00:02:49.600> in<00:02:49.900> industry<00:02:50.260> but<00:02:51.069> at<00:02:51.130> the<00:02:51.220> centre

00:02:51.479 --> 00:02:51.489 
have in industry but at the centre

00:02:51.489 --> 00:02:53.610 
have in industry but at the centre
itself<00:02:51.640> then<00:02:52.120> employs<00:02:52.630> approximately<00:02:52.750> 25

00:02:53.610 --> 00:02:53.620 
itself then employs approximately 25

00:02:53.620 --> 00:02:56.430 
itself then employs approximately 25
staff<00:02:53.950> I<00:02:54.280> joined<00:02:55.150> the<00:02:55.299> PM<00:02:55.540> BRC<00:02:55.989> in<00:02:56.140> order<00:02:56.349> to

00:02:56.430 --> 00:02:56.440 
staff I joined the PM BRC in order to

00:02:56.440 --> 00:02:58.020 
staff I joined the PM BRC in order to
continue<00:02:56.860> my<00:02:56.980> work<00:02:57.010> in<00:02:57.370> the<00:02:57.459> development<00:02:57.700> of

00:02:58.020 --> 00:02:58.030 
continue my work in the development of

00:02:58.030 --> 00:03:00.059 
continue my work in the development of
smart<00:02:58.269> materials<00:02:58.870> for<00:02:59.560> analytical

00:03:00.059 --> 00:03:00.069 
smart materials for analytical

00:03:00.069 --> 00:03:01.979 
smart materials for analytical
applications<00:03:00.640> and<00:03:00.819> sensing<00:03:01.209> devices<00:03:01.510> and

00:03:01.979 --> 00:03:01.989 
applications and sensing devices and

00:03:01.989 --> 00:03:04.500 
applications and sensing devices and
being<00:03:02.980> focused<00:03:03.370> on<00:03:03.459> applied<00:03:03.760> research<00:03:03.790> the

00:03:04.500 --> 00:03:04.510 
being focused on applied research the

00:03:04.510 --> 00:03:06.210 
being focused on applied research the
center<00:03:04.930> offers<00:03:05.170> my<00:03:05.500> full<00:03:05.709> support<00:03:05.860> for

00:03:06.210 --> 00:03:06.220 
center offers my full support for

00:03:06.220 --> 00:03:08.160 
center offers my full support for
patenting<00:03:06.790> and<00:03:06.940> commercializing<00:03:07.690> my<00:03:07.959> work

00:03:08.160 --> 00:03:08.170 
patenting and commercializing my work

00:03:08.170 --> 00:03:09.960 
patenting and commercializing my work
which<00:03:08.410> would<00:03:08.530> be<00:03:08.709> crucial<00:03:09.580> for<00:03:09.849> the

00:03:09.960 --> 00:03:09.970 
which would be crucial for the

00:03:09.970 --> 00:03:12.809 
which would be crucial for the
development<00:03:10.000> of<00:03:10.660> my<00:03:10.840> future<00:03:11.230> career<00:03:11.819> national

00:03:12.809 --> 00:03:12.819 
development of my future career national

00:03:12.819 --> 00:03:14.699 
development of my future career national
and<00:03:12.970> international<00:03:13.510> academic<00:03:13.630> contacts<00:03:14.500> and

00:03:14.699 --> 00:03:14.709 
and international academic contacts and

00:03:14.709 --> 00:03:16.680 
and international academic contacts and
sir<00:03:14.950> continuous<00:03:15.549> interaction<00:03:16.090> with<00:03:16.209> experts

00:03:16.680 --> 00:03:16.690 
sir continuous interaction with experts

00:03:16.690 --> 00:03:18.569 
sir continuous interaction with experts
from<00:03:16.870> various<00:03:16.930> disciplines<00:03:17.530> and<00:03:18.070> make

00:03:18.569 --> 00:03:18.579 
from various disciplines and make

00:03:18.579 --> 00:03:20.759 
from various disciplines and make
working<00:03:18.970> at<00:03:19.030> the<00:03:19.120> PMB<00:03:19.510> RCR<00:03:19.989> very<00:03:20.230> rewarding

00:03:20.759 --> 00:03:20.769 
working at the PMB RCR very rewarding

00:03:20.769 --> 00:03:24.420 
working at the PMB RCR very rewarding
experience<00:03:22.500> the<00:03:23.500> key<00:03:23.709> one<00:03:24.010> the<00:03:24.130> key<00:03:24.280> emphasis

00:03:24.420 --> 00:03:24.430 
experience the key one the key emphasis

00:03:24.430 --> 00:03:26.789 
experience the key one the key emphasis
of<00:03:24.700> the<00:03:25.000> Center<00:03:25.329> is<00:03:25.540> both<00:03:25.959> applied<00:03:26.380> research

00:03:26.789 --> 00:03:26.799 
of the Center is both applied research

00:03:26.799 --> 00:03:29.880 
of the Center is both applied research
and<00:03:27.209> basic<00:03:28.209> research<00:03:28.329> and<00:03:28.780> those<00:03:29.290> graduates

00:03:29.880 --> 00:03:29.890 
and basic research and those graduates

00:03:29.890 --> 00:03:32.789 
and basic research and those graduates
are<00:03:30.100> in<00:03:30.489> in<00:03:31.150> demand<00:03:31.510> and<00:03:31.810> in<00:03:32.079> need<00:03:32.290> in<00:03:32.590> the

00:03:32.789 --> 00:03:32.799 
are in in demand and in need in the

00:03:32.799 --> 00:03:34.830 
are in in demand and in need in the
Southeast<00:03:33.220> region<00:03:33.609> with<00:03:34.120> a<00:03:34.150> large<00:03:34.420> number<00:03:34.690> of

00:03:34.830 --> 00:03:34.840 
Southeast region with a large number of

00:03:34.840 --> 00:03:36.630 
Southeast region with a large number of
those<00:03:35.019> graduates<00:03:35.650> that<00:03:35.859> we<00:03:35.950> have<00:03:36.220> had<00:03:36.430> in<00:03:36.579> the

00:03:36.630 --> 00:03:36.640 
those graduates that we have had in the

00:03:36.640 --> 00:03:38.970 
those graduates that we have had in the
past<00:03:36.880> from<00:03:37.120> the<00:03:37.329> center<00:03:37.660> going<00:03:38.200> on<00:03:38.410> on<00:03:38.650> to<00:03:38.829> work

00:03:38.970 --> 00:03:38.980 
past from the center going on on to work

00:03:38.980 --> 00:03:41.190 
past from the center going on on to work
in<00:03:39.160> two<00:03:39.880> large<00:03:40.030> green<00:03:40.389> multinationals<00:03:41.049> in

00:03:41.190 --> 00:03:41.200 
in two large green multinationals in

00:03:41.200 --> 00:03:43.710 
in two large green multinationals in
Southeast<00:03:41.620> Region<00:03:41.950> as<00:03:42.069> well<00:03:42.569> initio<00:03:43.569> was

00:03:43.710 --> 00:03:43.720 
Southeast Region as well initio was

00:03:43.720 --> 00:03:45.990 
Southeast Region as well initio was
funded<00:03:44.079> through<00:03:44.230> at<00:03:44.829> the<00:03:44.980> enterprise<00:03:45.579> ireland

00:03:45.990 --> 00:03:46.000 
funded through at the enterprise ireland

00:03:46.000 --> 00:03:48.300 
funded through at the enterprise ireland
applied<00:03:46.630> research<00:03:46.930> enhancement<00:03:47.440> scheme<00:03:47.620> so

00:03:48.300 --> 00:03:48.310 
applied research enhancement scheme so

00:03:48.310 --> 00:03:51.300 
applied research enhancement scheme so
it<00:03:48.400> was<00:03:48.549> one<00:03:48.790> of<00:03:49.120> I<00:03:49.420> think<00:03:49.450> 13<00:03:49.989> centers<00:03:50.680> of

00:03:51.300 --> 00:03:51.310 
it was one of I think 13 centers of

00:03:51.310 --> 00:03:54.300 
it was one of I think 13 centers of
excellence<00:03:52.260> ours<00:03:53.260> being<00:03:53.470> one<00:03:53.829> of<00:03:53.920> the<00:03:54.010> only

00:03:54.300 --> 00:03:54.310 
excellence ours being one of the only

00:03:54.310 --> 00:03:56.309 
excellence ours being one of the only
ones<00:03:54.609> which<00:03:54.850> dealt<00:03:55.180> specifically<00:03:55.780> with<00:03:55.930> they

00:03:56.309 --> 00:03:56.319 
ones which dealt specifically with they

00:03:56.319 --> 00:03:58.770 
ones which dealt specifically with they
say<00:03:56.470> the<00:03:56.590> pharmaceutical<00:03:57.130> sector<00:03:57.780> that

00:03:58.770 --> 00:03:58.780 
say the pharmaceutical sector that

00:03:58.780 --> 00:04:01.289 
say the pharmaceutical sector that
funding<00:03:59.230> has<00:03:59.470> been<00:03:59.739> supported<00:04:00.489> since<00:04:00.670> then<00:04:00.910> by

00:04:01.289 --> 00:04:01.299 
funding has been supported since then by

00:04:01.299 --> 00:04:04.110 
funding has been supported since then by
a<00:04:01.329> number<00:04:01.810> of<00:04:01.959> other<00:04:02.230> funding<00:04:03.040> strands<00:04:03.489> some

00:04:04.110 --> 00:04:04.120 
a number of other funding strands some

00:04:04.120 --> 00:04:05.550 
a number of other funding strands some
of<00:04:04.239> the<00:04:04.359> was<00:04:04.540> involved<00:04:04.930> direct<00:04:05.139> funding<00:04:05.410> from

00:04:05.550 --> 00:04:05.560 
of the was involved direct funding from

00:04:05.560 --> 00:04:08.970 
of the was involved direct funding from
industry<00:04:06.359> others<00:04:07.359> are<00:04:07.630> applied<00:04:08.470> research

00:04:08.970 --> 00:04:08.980 
industry others are applied research

00:04:08.980 --> 00:04:11.190 
industry others are applied research
funded<00:04:09.880> projects<00:04:10.329> to<00:04:10.450> enterprise<00:04:10.810> Ireland

00:04:11.190 --> 00:04:11.200 
funded projects to enterprise Ireland

00:04:11.200 --> 00:04:13.410 
funded projects to enterprise Ireland
and<00:04:11.410> industry<00:04:11.829> as<00:04:11.920> a<00:04:11.950> partnership<00:04:12.370> and<00:04:12.639> then

00:04:13.410 --> 00:04:13.420 
and industry as a partnership and then

00:04:13.420 --> 00:04:16.409 
and industry as a partnership and then
we<00:04:13.600> have<00:04:13.870> others<00:04:14.530> which<00:04:14.700> involve<00:04:15.700> EU<00:04:16.030> funding

00:04:16.409 --> 00:04:16.419 
we have others which involve EU funding

00:04:16.419 --> 00:04:18.330 
we have others which involve EU funding
which<00:04:16.570> has<00:04:16.690> been<00:04:16.870> our<00:04:17.109> key<00:04:17.530> focus<00:04:17.950> in<00:04:18.099> the<00:04:18.190> last

00:04:18.330 --> 00:04:18.340 
which has been our key focus in the last

00:04:18.340 --> 00:04:19.940 
which has been our key focus in the last
two<00:04:18.549> years<00:04:18.789> of<00:04:18.940> the<00:04:19.000> Center

00:04:19.940 --> 00:04:19.950 
two years of the Center

00:04:19.950 --> 00:04:22.770 
two years of the Center
there's<00:04:20.950> been<00:04:21.070> a<00:04:21.100> significant<00:04:21.730> investment<00:04:22.120> in

00:04:22.770 --> 00:04:22.780 
there's been a significant investment in

00:04:22.780 --> 00:04:25.020 
there's been a significant investment in
laboratory<00:04:23.260> equipment<00:04:23.740> in<00:04:24.070> the<00:04:24.370> PMB<00:04:24.760> our<00:04:24.850> CEO

00:04:25.020 --> 00:04:25.030 
laboratory equipment in the PMB our CEO

00:04:25.030 --> 00:04:26.280 
laboratory equipment in the PMB our CEO
for<00:04:25.270> the<00:04:25.300> last<00:04:25.480> number<00:04:25.630> of<00:04:25.780> years<00:04:25.870> and

00:04:26.280 --> 00:04:26.290 
for the last number of years and

00:04:26.290 --> 00:04:28.140 
for the last number of years and
importantly<00:04:27.130> just<00:04:27.520> been<00:04:27.670> a<00:04:27.700> part<00:04:27.940> an

00:04:28.140 --> 00:04:28.150 
importantly just been a part an

00:04:28.150 --> 00:04:30.030 
importantly just been a part an
investment<00:04:28.660> into<00:04:28.840> human<00:04:29.200> capital<00:04:29.560> within<00:04:29.860> the

00:04:30.030 --> 00:04:30.040 
investment into human capital within the

00:04:30.040 --> 00:04:32.610 
investment into human capital within the
center<00:04:30.370> and<00:04:30.550> this<00:04:31.510> human<00:04:31.870> capital<00:04:32.080> and<00:04:32.500> this

00:04:32.610 --> 00:04:32.620 
center and this human capital and this

00:04:32.620 --> 00:04:34.440 
center and this human capital and this
equipment<00:04:33.190> is<00:04:33.280> now<00:04:33.430> expose<00:04:34.060> and<00:04:34.270> offer

00:04:34.440 --> 00:04:34.450 
equipment is now expose and offer

00:04:34.450 --> 00:04:38.520 
equipment is now expose and offer
industry<00:04:34.960> partners<00:04:35.350> and<00:04:35.530> academic<00:04:36.160> partners

